New data published regarding the risk of fetal loss following antimalarial use in pregnancy

Researchers from the US Center for Disease Control and Prevention and the Naval Health Research Centre in San Diego have published an analysis of the fetal loss (spontaneous abortion and stillbirth combined) rates among active duty military women using antimalarial medications during pregnancy. More information can be found here. Photo by Егор Камелев on Unsplash

» Read more

No detectable increased risk of birth defects following maternal IV administration of ondansetron

Researchers from the Brigham and Women’s Hospital in Boston (MA) and the Harvard T.H. Chan School of Public Health have published an update to their 2018 study (see here). The authors state that this update was provided to specifically address the findings of another study published in early 2019 (see here) which suggested an association between the clinical administration of […]

» Read more

Paracetamol use in the third trimester does not seem to be associated with a relevant risk of prenatal ductus arteriosus closure or fetal renal impairment

The team at Embryotox Berlin (TIS Berlin) in conjunction with a colleague from Beuth Hochschule für Technik-University of Applied Sciences in Berlin have conducted a study to examine the risk of fetal cardiovascular or renal toxicity following maternal third trimester paracetamol use. More information can be found here. Photo by Robina Weermeijer on Unsplash

» Read more

Continued folic acid supplementation beyond the early stages of pregnancy may have beneficial effects on child cognitive development

A collaboration of reserchers from Ulster University, Causeway Hospital in Northern Ireland, the Royal-Jubilee Maternity Service in Belfast, Universtiy College Dublin and Trinity College Dublin have published an update of their FASSTT Offspring Trial. This randomised controlled trial originally compared pregnancy outcomes between women treated with 400 micrograms of folic acid and placebo exposed controls. This latest update to the […]

» Read more

Collaborative ENTIS Study: Fetotoxic effects of ARBs exceeds that of ACE-Is

A collaboration of researchers from six ENTIS affiliated organisations and led by researchers at the Berlin TIS (Embryotox) have published their findings investigating the risk of fetotoxicity following maternal ARB or ACE-I use in pregnancy. The results of this research has suggested that, following use for at least 20 weeks of gestation, exposure to ARBs is associated with a higher […]

» Read more
1 2 3 6